| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | SEARCH RESULT |
Regular Articles |
1 Drug Discovery Program, H. Lee Moffitt Cancer Center and Research Institute, and
2 Departments of Oncology and Biochemistry and Molecular Biology, University of South Florida, Tampa, Florida, and
3 Department of Chemistry, Yale University, New Haven, Connecticut
Treatment of H-Ras transgenic mice with the geranylgeranyltransferase I (GGTase I) inhibitor GGTI-2154 results not only in halting the growth of aggressive breast tumors but actually in inducing the regression (54 ± 3%) of all 19 tumors analyzed. The farnesyltransferase (FTase) inhibitor FTI-2148 induced an average of 87 ± 3% regression in the 13 tumors analyzed. GGTase I, but not FTase, is inhibited in breast tumors after treatment with GGTI-2154, whereas in tumors from mice treated with FTI-2148, only FTase is inhibited. The processing of the geranylgeranylated proteins RhoA, Rap1, and R-Ras, but not the farnesylated proteins H-Ras and HDJ-2, is inhibited in tumors obtained from mice treated with GGTI-2154. GGTI-2154 and FTI-2148 suppress constitutively activated phospho-Erk1/2 and phospho-Akt, induce apoptosis, and induce differentiation toward ductolobular breast epithelium. The data demonstrate that geranylgeranylated proteins are critical in H-Ras oncogenesis in vivo and give strong support for GGTase I as a target for anticancer drug discovery.
This article has been cited by other articles:
|
|
 |
|
  J. Lu, L. Chan, H. D.G. Fiji, R. Dahl, O. Kwon, and F. Tamanoi In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I Mol. Cancer Ther., May 1, 2009; 8(5): 1218 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Sparano, S. Moulder, A. Kazi, D. Coppola, A. Negassa, L. Vahdat, T. Li, C. Pellegrino, S. Fineberg, P. Munster, et al. Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer Clin. Cancer Res., April 15, 2009; 15(8): 2942 - 2948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Roberts, N. Mitin, P. J. Keller, E. J. Chenette, J. P. Madigan, R. O. Currin, A. D. Cox, O. Wilson, P. Kirschmeier, and C. J. Der Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification J. Biol. Chem., September 12, 2008; 283(37): 25150 - 25163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Watanabe, H. D. G. Fiji, L. Guo, L. Chan, S. S. Kinderman, D. J. Slamon, O. Kwon, and F. Tamanoi Inhibitors of Protein Geranylgeranyltransferase I and Rab Geranylgeranyltransferase Identified from a Library of Allenoate-derived Compounds J. Biol. Chem., April 11, 2008; 283(15): 9571 - 9579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Falsetti, D.-a. Wang, H. Peng, D. Carrico, A. D. Cox, C. J. Der, A. D. Hamilton, and S. M. Sebti Geranylgeranyltransferase I Inhibitors Target RalB To Inhibit Anchorage-Dependent Growth and Induce Apoptosis and RalA To Inhibit Anchorage-Independent Growth Mol. Cell. Biol., November 15, 2007; 27(22): 8003 - 8014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W.-L. Wong, J. W. Clendening, A. Martirosyan, P. C. Boutros, C. Bros, F. Khosravi, I. Jurisica, A. K. Stewart, P. L. Bergsagel, and L. Z. Penn Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma Mol. Cancer Ther., June 1, 2007; 6(6): 1886 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Sparano, S. Moulder, A. Kazi, L. Vahdat, T. Li, C. Pellegrino, P. Munster, M. Malafa, D. Lee, S. Hoschander, et al. Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide J. Clin. Oncol., July 1, 2006; 24(19): 3013 - 3018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Peterson, P. Kelly, C. A. Weinbaum, and P. J. Casey A Novel Protein Geranylgeranyltransferase-I Inhibitor with High Potency, Selectivity, and Cellular Activity J. Biol. Chem., May 5, 2006; 281(18): 12445 - 12450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Wright and M. R. Philips Thematic review series: Lipid Posttranslational Modifications CAAX modification and membrane targeting of Ras J. Lipid Res., May 1, 2006; 47(5): 883 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Fong, D. Frost, M. Meta, X. Qiao, S. H. Yang, C. Coffinier, and S. G. Young A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria Science, March 17, 2006; 311(5767): 1621 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Graner and D. D. Bigner Chaperone proteins and brain tumors: Potential targets and possible therapeutics Neuro-oncol, July 1, 2005; 7(3): 260 - 278. [Abstract] [PDF]
|
|
|
|
|
|
D. Ferguson, L. E. Rodriguez, J. P. Palma, M. Refici, K. Jarvis, J. O'Connor, G. M. Sullivan, D. Frost, K. Marsh, J. Bauch, et al. Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models Clin. Cancer Res., April 15, 2005; 11(8): 3045 - 3054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Venkatasubbarao, A. Choudary, and J. W. Freeman Farnesyl Transferase Inhibitor (R115777)-Induced Inhibition of STAT3(Tyr705) Phosphorylation in Human Pancreatic Cancer Cell Lines Require Extracellular Signal-Regulated Kinases Cancer Res., April 1, 2005; 65(7): 2861 - 2871. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | SEARCH RESULT |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
